Floatz Rating
D29/100
Confidence
Indicative
Sponsor
Boehringer Ingelheim
Modality
Small molecule
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
14Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05282121CT.gov A Study to Test Whether BI 685509 Alone or in Combination With Empagliflozin Helps People With Liver Cirrhosis Caused by Viral Hepatitis or Non-alcoholic Steatohepatitis (NASH) Who Have High Blood Pressure in the Portal Vein (Main Vessel Going to the Liver) | — | Terminated | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
89High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Liver Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Avenciguat (this asset) | Boehringer Ingelheim | P2 | D · 29 |
| Pioglitazone | Yonsei University | P4 | BBB |
| Metformin | Taipei City Hospital | P4 | BBB |
| Empagliflozin | Military University Hospital, Prague | P4 | BB |
| 10-(1-methylpiperidin-4-ylidene)-5,10-dihydro-4H-benzo[5,6]cyclohepta[1,2-b]thiophen-4-one | Tanta University | P4 | BB |
| Glibenclamide | Takeda | P4 | BB |
| Hep-V Vax | University of Oxford | P4 | BB |
| Alpha Tocopherol | Tanta University | P4 | BB |
| Heplisav-B | Mercy Medical Center | P4 | BB |
+42 more in the Liver Disorder cohort
Other indications for Avenciguat
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Portal Hypertension | — | P2 | D · 29 |
| Cirrhosis Of Liver | — | P2 | D · 29 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Avenciguat in Liver Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/avenciguat-liver-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →